The 10-year overall survival rate of osteosarcoma patients in the low-expression SOX4 group was 79.5%, and that in the high-expression group was 54.5%, as assessed by the Log-rank test (P=0.04). This evidence concerns the gene SOX4 and osteosarcoma.